New hope for mitochondrial disease: KL1333 aims to ease fatigue and boost daily life
NCT ID NCT07514338
First seen Apr 13, 2026 · Last updated May 16, 2026 · Updated 4 times
Summary
This study tests the long-term safety and effectiveness of the drug KL1333 in people with primary mitochondrial disease, a condition that causes severe fatigue and physical limitations. About 140 adults who completed a prior study will take KL1333 and be monitored for side effects and improvements in fatigue, daily activities, and physical function. The goal is to see if the drug can help manage symptoms over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.